PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease
September 16, 2024 04:00 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...
C4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board members
July 22, 2024 04:00 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings Limited C4XD announces progress on immuno-inflammation programmes and appointment of new Board members 22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug...
C4X Discovery Holdings plc: Half-year results for the six months ended 31 January 2023
April 26, 2023 02:00 ET
|
C4X Discovery Holdings plc
This announcement contains inside information C4X Discovery Holdings plc("C4XD", "C4X Discovery" or the "Company") Half-year results for the six months ended 31 January 2023 Up to $402 million...
C4XD and Garvan Institute of Medical Research report successful patient stratification approach using C4XD's new precision medicine platform PatientSeek
February 22, 2023 02:00 ET
|
C4X Discovery Holdings plc
First validation of C4XD's patient sub-groups through a Garvan-led retrospective clinical trial analysis Promising initial result paves way for novel approaches in Parkinson's disease...
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
November 28, 2022 02:00 ET
|
C4X Discovery Holdings plc
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's...
C4X Discovery receives Sanofi milestone payment
July 06, 2022 03:29 ET
|
C4X Discovery Holdings plc
C4X Discovery Holdings plc C4X Discovery receives first milestone payment from Sanofi €3 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme ...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme
April 12, 2021 07:00 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme
April 12, 2021 04:30 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential...
C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline
June 25, 2019 02:00 ET
|
C4X Discovery Holdings PLC
C4X Discovery Holdings plc (“C4XD”, “C4X Discovery” or the “Company”) C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline 25 June 2019 – C4X...
C4X Discovery signs licensing agreement with Indivior for addiction programme worth up to $294m
March 29, 2018 10:07 ET
|
C4X Discovery Holdings plc
C4X Discovery Holdings plc ("C4XD" or the "Company") C4XD receives $10 million upfront, potential milestones totalling $284 million plus royalties 29 March 2018 - C4X Discovery...